Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc, is a Professor of Medicine and an internationally recognized leader in Steatotic Liver Disease (SLD) and SLD-related cirrhosis. He completed his internal medicine residency at the University of Southern California (USC), followed by advanced hepatology training at the National Institutes of Health (NIH) within the NIDDK Liver Diseases Branch, where he also earned an NIH/Duke Master of Health Sciences in Clinical Research. He subsequently completed a gastroenterology fellowship at the University of California, San Diego (UCSD) as a T32 NIH fellow. He joined USC as Assistant Professor in 2013 and was recruited to Cedars-Sinai Medical Center in 2015 as the founding Director of the Fatty Liver Program.Dr. Noureddin is internationally known for translational and clinical research in SLD, including disease mechanisms, non-invasive diagnostics, biomarkers, and therapeutic development. He has led or participated in more than 100 investigational clinical trials, serving as Global Principal Investigator or steering committee member on numerous landmark SLD studies. He has received NIH funding and also served as a reviewer on NIH study sections.Dr. Noureddin has received numerous prestigious awards and honors for his contributions to liver disease research, most recently the inaugural Impact Award from the American Association for the Study of Liver Diseases (AASLD) in 2026. He has served on international consensus panels for AASLD, EASL, APASL, and ALEH and is a frequent invited speaker at national and international scientific meetings. He has served as Chair of the AASLD MASLD Special Interest Group and on numerous industry steering and advisory committees. He serves on the editorial boards of leading journals, including Gastroenterology, Hepatology, and Clinical Gastroenterology and Hepatology, where he is also an Associate Editor.He has authored more than 350 peer-reviewed publications, including articles in The New England Journal of Medicine, The Lancet, Nature Medicine, Science Translational Medicine, Hepatology, Journal of Hepatology, and Gastroenterology, and has served as first or senior author on major clinical trials published in The New England Journal of Medicine, The Lancet and Nature Medicine.In 2022, Dr. Noureddin moved to Houston and became Professor of Medicine at Houston Methodist Hospital, where he is affiliated with the Lynda K. and David M. Underwood Center for Digestive Disorders, J.C. Walter Jr. Transplant Center, and Sherrie & Alan Conover Center for Liver Disease & Transplantation. Houston Methodist is ranked #5 in Gastroenterology and GI Surgery by U.S. News & World Report.He founded the Houston Research Institute, a state-of-the-art private research facility providing access to innovative non-invasive diagnostics and breakthrough liver disease and metabolic disease therapies. Dr. Noureddin serves as Chief Scientific Officer and Co-Chairman of the Board of Summit Clinical Research Solutions.